PURPOSE: To delineate formulation dependent pharmacokinetics and bioavailability of SC-560, a relatively new cycloooxygenase-1 (COX-1) specific inhibitor, in the rat and examine its influence on the renal tubular enzyme, N-acetyl-beta-D-glucosaminidase (NAG), and urinary electrolytes. METHODS: The pharmacokinetics of SC-560 was studied in Sprague-Dawley rats (n = 5 per group) after a single intravenous (i.v.) and oral dose (10 mg/kg) in polyethylene glycol (PEG) 600 and a single oral dose (10 mg/kg) in 1% methylcellulose (MC). Serial blood samples were collected via a catheter inserted in the right jugular vein and serum samples were analysed for SC-560 using reverse phase HPLC. After oral administration of SC-560 in PEG, urine was also collected for 24 h and analysed for urinary sodium, chloride, and potassium as well as NAG. RESULTS: After an iv dose (10 mg/kg) of SC-560, serum AUC, t(1/2), CL and Vd were 9704 +/- 4038 ng h/mL, 5.4 +/- 0.8 h, 1.15 +/- 0.46 L/h/kg and 9.1 +/- 4.6 L/kg (mean +/- SD, n = 5), respectively. Oral administration of 10 mg/kg SC-560-PEG and MC (n=5 rats) yielded serum AUC, C max, t (max )and t (1/2) of 1203.4 +/- 130.3 and 523 +/- 208 ng h/mL, 218.5 +/- 86.9 and 119.8 +/- 15.5 ng/mL, 1.00 +/- 1.8 and 2.0+/- 0 h, 3.7 +/- 1.6 and 2.7 +/- 1.7 h (mean +/- SD, n = 5), respectively. A single oral dose 10 mg/kg of SC-560 in PEG resulted in an increase in NAG excretion in urine and a reduction in 0-24 h urinary sodium, potassium, and chloride excretion. CONCLUSIONS: SC-560 extensively distributes into rat tissues, and has a CL approaching hepatic plasma flow. The drug displays low <15% and formulation dependent bioavailability after oral administration and demonstrates kidney toxicity.
PURPOSE: To delineate formulation dependent pharmacokinetics and bioavailability of SC-560, a relatively new cycloooxygenase-1 (COX-1) specific inhibitor, in the rat and examine its influence on the renal tubular enzyme, N-acetyl-beta-D-glucosaminidase (NAG), and urinary electrolytes. METHODS: The pharmacokinetics of SC-560 was studied in Sprague-Dawley rats (n = 5 per group) after a single intravenous (i.v.) and oral dose (10 mg/kg) in polyethylene glycol (PEG) 600 and a single oral dose (10 mg/kg) in 1% methylcellulose (MC). Serial blood samples were collected via a catheter inserted in the right jugular vein and serum samples were analysed for SC-560 using reverse phase HPLC. After oral administration of SC-560 in PEG, urine was also collected for 24 h and analysed for urinary sodium, chloride, and potassium as well as NAG. RESULTS: After an iv dose (10 mg/kg) of SC-560, serum AUC, t(1/2), CL and Vd were 9704 +/- 4038 ng h/mL, 5.4 +/- 0.8 h, 1.15 +/- 0.46 L/h/kg and 9.1 +/- 4.6 L/kg (mean +/- SD, n = 5), respectively. Oral administration of 10 mg/kg SC-560-PEG and MC (n=5 rats) yielded serum AUC, C max, t (max )and t (1/2) of 1203.4 +/- 130.3 and 523 +/- 208 ng h/mL, 218.5 +/- 86.9 and 119.8 +/- 15.5 ng/mL, 1.00 +/- 1.8 and 2.0+/- 0 h, 3.7 +/- 1.6 and 2.7 +/- 1.7 h (mean +/- SD, n = 5), respectively. A single oral dose 10 mg/kg of SC-560 in PEG resulted in an increase in NAG excretion in urine and a reduction in 0-24 h urinary sodium, potassium, and chloride excretion. CONCLUSIONS:SC-560 extensively distributes into rat tissues, and has a CL approaching hepatic plasma flow. The drug displays low <15% and formulation dependent bioavailability after oral administration and demonstrates kidney toxicity.
Authors: Md Jashim Uddin; Anna V Elleman; Kebreab Ghebreselasie; Cristina K Daniel; Brenda C Crews; Kellie D Nance; Tamanna Huda; Lawrence J Marnett Journal: ACS Med Chem Lett Date: 2014-10-12 Impact factor: 4.345
Authors: Thomas J Hannan; Pacita L Roberts; Terrence E Riehl; Sjoerd van der Post; Jana M Binkley; Drew J Schwartz; Hiroyuki Miyoshi; Matthias Mack; Reto A Schwendener; Thomas M Hooton; Thaddeus S Stappenbeck; Gunnar C Hansson; William F Stenson; Marco Colonna; Ann E Stapleton; Scott J Hultgren Journal: EBioMedicine Date: 2014-10-24 Impact factor: 8.143
Authors: Andrew J Wilson; Oluwole Fadare; Alicia Beeghly-Fadiel; Deok-Soo Son; Qi Liu; Shilin Zhao; Jeanette Saskowski; Md Jashim Uddin; Cristina Daniel; Brenda Crews; Brian D Lehmann; Jennifer A Pietenpol; Marta A Crispens; Lawrence J Marnett; Dineo Khabele Journal: Oncotarget Date: 2015-08-28
Authors: Clare Howarth; Brad Sutherland; Hyun B Choi; Chris Martin; Barbara Lykke Lind; Lila Khennouf; Jeffrey M LeDue; Janelle M P Pakan; Rebecca W Y Ko; Graham Ellis-Davies; Martin Lauritzen; Nicola R Sibson; Alastair M Buchan; Brian A MacVicar Journal: J Neurosci Date: 2017-01-30 Impact factor: 6.167
Authors: Mary E Konkle; Anna L Blobaum; Christopher W Moth; Jeffery J Prusakiewicz; Shu Xu; Kebreab Ghebreselasie; Dapo Akingbade; Aaron T Jacobs; Carol A Rouzer; Terry P Lybrand; Lawrence J Marnett Journal: Biochemistry Date: 2015-12-31 Impact factor: 3.162
Authors: Samaa Alrushaid; Casey L Sayre; Jaime A Yáñez; M Laird Forrest; Sanjeewa N Senadheera; Frank J Burczynski; Raimar Löbenberg; Neal M Davies Journal: Pharmaceutics Date: 2017-09-13 Impact factor: 6.321